Lijuan Li

Dr. Lijuan Li

Auto-generated profile, based on publicly available information

Dr. Lijuan Li


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FMFanqiao Meng
Fanqiao Meng
LLLijuan Li
Lijuan Li
FLFengzhu Lu
Fengzhu Lu
JYJing Yue
Jing Yue
ZLZhaoyun Liu
Zhaoyun Liu
RFRong Fu
Rong Fu
Objective: Targeting immune checkpoints, such as PD-1, represents a promising approach for cancer immunotherapy, achieving long-term disease remission rates in numerous types of cancer. T cell immunoglobulin and ITIM domain (TIGIT) is a checkpoint receptor associated with the antitumor roles of NK and T cells. Notably, the blockade of TIGIT has been revealed as a potential promising approach in cancer immunotherapy. However, the therapeutic potential of blocking TIGIT in myelodysplastic syndrome (MDS) remains unclear and further research is required to reveal their role. Methods: Fresh peripheral blood (PB) and bone marrow (BM) were obtained from patients with MDS and healthy donors (HDs) at the Tianjin Medical University General Hospital between January 21 2018 and March 22 2019. The present study investigated the expression levels of TIGIT on NK and T cells using flow cytometry (FCM) and PCR. In addition, other checkpoint receptors, such as CD226 and PD-1, were also investigated. To determine the mechanisms of antitumor immunity, the functions of NK and T cells expressing TIGIT were determined. Results: TIGIT was found to be highly expressed on NK and T cells of the PB, where it was involved in disease progression and the immune escape of MDS. The high expression levels of TIGIT were associated with decreased NK and T cell function, and significantly lower secretions of activation factors, such as CD107a, IFN-γ and TNF-α. Notably, blocking TIGIT enhanced the antitumor effects of NK and T cells. Conclusion: The results of the present study suggested that targeting TIGIT alone or in combination with PD-1 may be a promising anticancer therapeutic strategy in MDS.

3 May 2022 in Immunology
Verified
Journal Article
Closed access
Shunjie YuShunjie Yu
Shunjie Yu
XRXiaotong Ren
Xiaotong Ren
FMFanqiao Meng
Fanqiao Meng
XGXinyu Guo
Xinyu Guo
JTJinglian Tao
Jinglian Tao
LLLijuan Li
Lijuan Li

21 May 2014 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
LLLi Juan Li
Li Juan Li
JTJing Lian Tao
Jing Lian Tao
RFRong Fu
Rong Fu
HWHua Quan Wang
Hua Quan Wang
HJHui Juan Jiang
Hui Juan Jiang
ZSZong Hong Shao
Zong Hong Shao

19 July 2022 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
Shunjie YuShunjie Yu
Shunjie Yu
XRXiaotong Ren
Xiaotong Ren
LLLijuan Li
Lijuan Li
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of bone marrow cells originating from immature myeloid cells. They exert potent immunosuppressive activity and are closely associated with the development of various diseases such as malignancies, infections, and inflammation. In malignant tumors, MDSCs, one of the most dominant cellular components comprising the tumor microenvironment, play a crucial role in tumor growth, drug resistance, recurrence, and immune escape. Although the role of MDSCs in solid tumors is currently being extensively studied, little is known about their role in hematologic malignancies. In this review, we comprehensively summarized and reviewed the different roles of MDSCs in hematologic malignancies and hematopoietic stem cell transplantation, and finally discussed current targeted therapeutic strategies.Affiliation: Kindly check and confirm the processed affiliations are correct. Amend if any.correct

12 December 2014 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
RFRong Fu
Rong Fu
HLHui Liu
Hui Liu
SZSijie Zhao
Sijie Zhao
YWYihao Wang
Yihao Wang
LLLijuan Li
Lijuan Li
ZSZonghong Shao
Zonghong Shao
Multiple myeloma is a hematologic malignancy characterized by the accumulation of monoclonal plasma cells in the bone marrow. A common manifestation of the disease is myeloma bone disease (MBD), which is caused by increased osteoclastic bone resorption and decreased bone formation. The chemokine cytokine ligand 3 (CCL3) is a pro-inflammatory protein and chemokine that stimulates osteoclasts in MBD. However, little is known about the effect of CCL3 on osteoblasts (OB). The OBs are induced from patients with MBD and healthy donors, cultured in vitro, and identified by histochemistry. The effects of CCL3 and CCL3 antibody on the OBs in vitro are observed. The CCL3 receptor (CCR1), osteocalcin (OCN), runt-related transcription factor 2 (Runx2), and osterix (Osx) are detected using flow cytometry, enzyme-linked immunosorbent assay, and real-time PCR. Proliferation and osteogenic potential of the OB in patients with MBD are suppressed. Moreover, the CCR1 expression is significantly higher in patients with MBD than in normal controls. The OCN level, quantity of calcium nodules, and Runx2 and Osx levels decrease after CCL3 stimulation, which indicates that CCL3 inhibits OB function. Furthermore, CCL3 antibody partially restores OB activity through the upregulation of the OCN, Runx2, and Osx. CCL3 contributes to the OB/OC imbalance by inhibiting OB differentiation and function in MBD.

1 June 2020 in Leukemia Research
Verified
Journal Article
Closed access
JHJiaxin Hu
Jiaxin Hu
FMFanqiao Meng
Fanqiao Meng
XHXian Hu
Xian Hu
LHLei Huang
Lei Huang
HLHui Liu
Hui Liu
LLLijuanli Li
Lijuanli Li